These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8007681)

  • 21. Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors.
    Hayashi M; Shibazaki M; Sohma R; Inaba N
    Am J Med Sci; 2006 Oct; 332(4):181-5. PubMed ID: 17031243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses.
    Antonić J; Rakar S
    Anticancer Res; 1995; 15(4):1527-32. PubMed ID: 7654041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum CA 125 in ovarian pathology and its variation in ovarian carcinoma after integrated therapy.
    Pansini F; Bellinazzi A; Rainaldi V; Santoiemma M; Lenzi B; Jacobs M; Mollica G; Bagni B
    Gynecol Obstet Invest; 1986; 21(1):47-51. PubMed ID: 3005141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors.
    Tashiro Y; Yonezawa S; Kim YS; Sato E
    Hum Pathol; 1994 Apr; 25(4):364-72. PubMed ID: 8163269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies.
    Scambia G; Benedetti Panici P; Perrone L; Sonsini C; Giannelli S; Gallo A; Natali PG; Mancuso S
    Br J Cancer; 1990 Jul; 62(1):147-51. PubMed ID: 2167724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computed tomography of benign ovarian masses.
    Sawyer RW; Vick CW; Walsh JW; McClure PH
    J Comput Assist Tomogr; 1985; 9(4):784-9. PubMed ID: 4019837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
    Chen DX; Schwartz PE; Li XG; Yang Z
    Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation.
    Mastropaolo W; Fernandez Z; Miller EL
    Clin Chem; 1986 Nov; 32(11):2110-1. PubMed ID: 3465487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
    Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC
    Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
    Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
    J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study.
    Schutter EM; Sohn C; Kristen P; Möbus V; Crombach G; Kaufmann M; Caffier H; Kreienberg R; Verstraeten AA; Kenemans P
    Gynecol Oncol; 1998 Apr; 69(1):56-63. PubMed ID: 9570999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A case of malignant ovarian tumor complicated by pregnancy, from the standpoint of tumor marker and quality of life].
    Okamoto M; Narushima M; Fukasawa H; Suzuki A; Hoshi S
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3287-90. PubMed ID: 2782921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
    Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
    J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery.
    Yedema CA; Kenemans P; Thomas CM; Massuger LF; Wobbes T; Verstraeten R; van Kamp GJ; Hilgers J
    Eur J Cancer; 1993; 29A(7):966-71. PubMed ID: 8499150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined evaluation of serum CA 125 and CAM 29 in patients with epithelial ovarian cancer.
    Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Annicchiarico C; Prato B; Bianchi R; Fioretti P
    Tumour Biol; 1992; 13(5-6):287-93. PubMed ID: 1290026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Benign ovarian tumor with ascites and high serum levels of CA125: report of 3 cases].
    Li HJ; Shen K; Lang JH; Wu M; Huang HF; Pan LY
    Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):147-9. PubMed ID: 12816688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Studies on the serum levels of a carbohydrate antigen 19-9 (CA 19-9) in patients with ovarian cancer].
    Miyoshi T; Nishimura H; Ookura N; Morisaki H; Kobayashi H; Tasaki T; Ushijima H; Yakushiji M
    Igaku Kenkyu; 1984 Dec; 54(8):796-800. PubMed ID: 6599577
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinicopathological features and immunoprofile of 30 cases of Brenner ovarian tumors.
    Kondi-Pafiti A; Kairi-Vassilatou E; Iavazzo Ch; Vouza E; Mavrigiannaki P; Kleanthis Ch; Vlahodimitropoulos D; Liapis A
    Arch Gynecol Obstet; 2012 Jun; 285(6):1699-702. PubMed ID: 22198845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective study of serum CA-125 levels as markers of ovarian cancer.
    Helzlsouer KJ; Bush TL; Alberg AJ; Bass KM; Zacur H; Comstock GW
    JAMA; 1993 Mar; 269(9):1123-6. PubMed ID: 8433467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease.
    Malkasian GD; Knapp RC; Lavin PT; Zurawski VR; Podratz KC; Stanhope CR; Mortel R; Berek JS; Bast RC; Ritts RE
    Am J Obstet Gynecol; 1988 Aug; 159(2):341-6. PubMed ID: 2457318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.